ORNAVH Stock Overview
Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Orion Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €53.50 |
| 52 Week High | €53.80 |
| 52 Week Low | €42.05 |
| Beta | 0.48 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 63.36% |
| 5 Year Change | 95.97% |
| Change since IPO | 252.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORNAVH | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -2.6% |
| 1Y | n/a | -3.8% | 2.7% |
Return vs Industry: Insufficient data to determine how ORNAVH performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ORNAVH performed against the UK Market.
Price Volatility
| ORNAVH volatility | |
|---|---|
| ORNAVH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ORNAVH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ORNAVH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 3,527 | Liisa Hurme | www.orion.fi |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson’s disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Orion Oyj Fundamentals Summary
| ORNAVH fundamental statistics | |
|---|---|
| Market cap | €6.16b |
| Earnings (TTM) | €349.50m |
| Revenue (TTM) | €1.34b |
17.6x
P/E Ratio4.6x
P/S RatioIs ORNAVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORNAVH income statement (TTM) | |
|---|---|
| Revenue | €1.34b |
| Cost of Revenue | €491.70m |
| Gross Profit | €848.90m |
| Other Expenses | €499.40m |
| Earnings | €349.50m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Apr 27, 2023
| Earnings per share (EPS) | 2.49 |
| Gross Margin | 63.32% |
| Net Profit Margin | 26.07% |
| Debt/Equity Ratio | 22.7% |
How did ORNAVH perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield64%
Payout RatioDoes ORNAVH pay a reliable dividends?
See ORNAVH dividend history and benchmarks| Orion Oyj dividend dates | |
|---|---|
| Ex Dividend Date | Mar 23 2023 |
| Dividend Pay Date | Mar 31 2023 |
| Days until Ex dividend | 638 days |
| Days until Dividend pay date | 630 days |
Does ORNAVH pay a reliable dividends?
See ORNAVH dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/20 01:37 |
| End of Day Share Price | 2022/12/22 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orion Oyj is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Graham Glyn Parry | BofA Global Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |